Stoke Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Stoke Therapeutics, Inc. (STOK) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$4.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-16
- Stoke Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$4.50M, a 113.93% decline from fiscal 2024.
- Stoke Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $32.30M, a 8.76% decline from fiscal 2023.
- Stoke Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $35.40M, a 11.32% increase from fiscal 2022.
- Stoke Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $31.80M, a 10.42% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | -$4.50M 10-K · filed 2026-03-16 |
| 2024-12-31 | $32.30M 10-K · filed 2026-03-16 |
| 2023-12-31 | $35.40M 10-K · filed 2025-03-18 |
| 2022-12-31 | $31.80M 10-K · filed 2024-03-25 |
| 2021-12-31 | $28.80M 10-K · filed 2023-03-06 |
| 2020-12-31 | $19.30M 10-K · filed 2022-03-10 |
| 2019-12-31 | $10.30M 10-K · filed 2021-03-09 |
| 2018-12-31 | $3.50M 10-K · filed 2020-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |